GlassScriptPhysician profile
William C Sawyer
NPI 1841242146
$5,353.14
in general payments reported to CMS, 2019-2025
35 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $844 · 2021: $929 · 2022: $720 · 2023: $1,032 · 2024: $634 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,253.91 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $461.99 | 2020-2025 | Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $427.21 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $406.09 | 2019-2025 | Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $317.11 | 2020-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $254.37 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $212.22 | 2019-2022 | |
| Lilly USA, LLC | $202.20 | 2020-2025 | Mounjaro, Kisunla, Zepbound |
| Janssen Pharmaceuticals, INC | $192.69 | 2019-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $191.30 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $145.35 | 2023-2024 | Rexulti |
| Amgen INC. | $137.59 | 2019-2024 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $136.53 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.94 | 2020-2022 | |
| Abbott Laboratories | $94.01 | 2022-2025 | Freestyle Libre 3 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $86.62 | 2021-2025 | Arexvy, Shingrix, Rotarix |
| Dexcom, INC. | $84.94 | 2021-2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $81.93 | 2024 | Voquezna |
| Pfizer INC. | $79.54 | 2019-2024 | |
| Exact Sciences Corporation | $67.04 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $54.48 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Optinose US, INC. | $49.40 | 2019-2020 | |
| Corcept Therapeutics | $44.92 | 2025 | Korlym |
| Allergan, INC. | $41.19 | 2019 | |
| Esperion Therapeutics, INC. | $39.28 | 2021 | |
| Genentech USA, INC. | $29.98 | 2020-2021 | |
| Ethicon US, LLC | $28.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.60 | 2020 | |
| Amarin Pharma, INC. | $19.15 | 2020 | |
| Sunovion Pharmaceuticals INC. | $18.43 | 2019 | |
| Mylan Specialty L.P. | $17.97 | 2019 | |
| Daiichi Sankyo INC. | $17.76 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.65 | 2022 | |
| Eisai INC. | $15.70 | 2021 | |
| Organon LLC | $12.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sawyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.